IN8bio, Inc. (INAB)
IN8bio will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 14.75M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | n/a |
| Last Price | n/a |
| Previous Close | n/a |
| Change ($) | n/a |
| Change (%) | n/a |
| Day's Open | n/a |
| Day's Range | n/a |
| Day's Volume | n/a |
| 52-Week Range | n/a |
IN8bio, Inc. has filed to go public with an IPO on the New York Stock Exchange (NYSE).
IN8bio has trod an unusual path to an IPO but now has revived its once-dropped attempt.
About INAB
IN8bio is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. Gamma-delta T cells are naturally occurring cells in the human immune system that recognize and kill cancerous cells, while possessing a tumor recognition mechanism that protects healthy tissue. Gamma-delta T cells embody properties of both the innate and adaptive immune systems, which allows for them to serve as a funct... [Read more...]
| IPO Date Pending | |
| Stock Exchange NYSE | Ticker Symbol INAB |